Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety profile and efficacy of whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases (BM).Patients with BM were randomly assigned to 30 Gy of WBRT with or without concomitant TMZ (75 mg/m2/d) plus two cycles of TMZ (200 mg/m2/d for 5 days).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang Cancer Hospital
• Collaborator: Hangzhou Cancer Hospital
• Treatments: Dacarbazine; Temozolomide

Criteria

Inclusion Criteria:

• histologically diagnosed as NSCLC, stage IVb [ (American Joint of Cancer Committee(AJCC), 2002) ], Brain metastasis

• no history of hypertension or diabetes.

Exclusion Criteria:

• the brain tumor diameter >5cm; RPA class =3; pregnancy.